Does Pramlintide work?
Yes, in six controlled trials; the largest had 480 people.
Approval rested on randomized, placebo-controlled trials in type 1 and type 2 diabetes lasting up to a year; the label summarizes six placebo-controlled trials (four in type 1 and two in type 2 diabetes), the largest with 480 type 1 patients, in which pramlintide lowered HbA1c by about 0.25 to 0.34 percentage points more than placebo and reduced weight. The effect is real but small, and the drug has largely been displaced by GLP-1 agonists. 1
The label summarizes placebo-controlled trials of 26 to 52 weeks in type 1 and type 2 diabetes. In three type 1 trials, adding pramlintide to insulin lowered HbA1c at six months. The drop was 0.25 to 0.34 percentage points more than with placebo. Weight fell by about 0.8 to 1.6 kg, while placebo patients gained up to 0.8 kg. A fourth type 1 study cut insulin at the start and then adjusted it freely. HbA1c fell equally in both groups. But the pramlintide group needed less mealtime insulin and lost 1.3 kg. In two type 2 trials on insulin, the HbA1c difference was 0.30 to 0.34 points. Weight losses were 1.4 to 1.6 kg, against small gains on placebo. 1
Evidence checklist
- Randomised controlled trial Placebo-controlled phase 3 trials
- Human study over 100 people Several hundred in the largest trial
- More than one research group Four phase 3 trials, across sites
- Clinical outcomes, not surrogate markers HbA1c and weight, surrogates
- Human safety data beyond case reports Boxed warning from pooled trial data
Read the full Pramlintide page
More on Pramlintide
Citations
- Symlin (pramlintide acetate) prescribing information, FDA, 2014 revision accessdata.fda.gov
Reference information only, not medical advice. Drawn from the Pramlintide article, fact-checked against the cited sources. No dosing anywhere on this site.